HLB Therapeutics

HLB테라퓨틱스 · 115450

Industrials Trading & Distribution · KOSDAQ

Small-cap

Market cap US$161.8M (₩223.2B)

Overview

HLB Therapeutics is a South Korean company listed on KOSDAQ that operates across three business lines: biopharmaceutical drug development, cold-chain logistics and pharmaceutical distribution, and electronics components such as motors and pumps.

Its biopharmaceutical work involves developing new drugs, with clinical programs run through US-based subsidiaries, while its distribution arm supplies medicines through domestic channels. The company is actively restructuring toward a bio-focused business, having spun off its electronics operations into a wholly owned subsidiary.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$50.4M

▲ +26.6% YoY

Operating profit · FY2025

−US$2.6M

Loss narrowed

Net income · FY2025

−US$7M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$38.9M(₩53.7B)	US$39.8M(₩54.9B)	US$50.4M(₩69.6B)
Operating profit	−US$6.3M(−₩8.7B)	−US$5.5M(−₩7.6B)	−US$2.6M(−₩3.5B)
Net income	−US$2.2M(−₩3.1B)	−US$17M(−₩23.5B)	−US$7M(−₩9.7B)

Revenue

FY2023US$38.9M
FY2024US$39.8M
FY2025US$50.4M

Operating profit

FY2023−US$6.3M
FY2024−US$5.5M
FY2025−US$2.6M

Net income

FY2023−US$2.2M
FY2024−US$17M
FY2025−US$7M

Key ratios (FY2025)

ROE

-5.6%

Debt/Eq

31.5%

Op. margin

-5.1%

Net margin

-13.9%

Rev. YoY

▲ +26.6%

Why it matters

The electronics division was separated into a newly established wholly owned subsidiary, ㈜코아인더스, through a physical spin-off approved at an extraordinary shareholders' meeting.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?